assembly, as applicable. Repetitive inspections are no longer required on an MLG ''A'' frame assembly incorporating this design configuration. Repetitive inspections are still required on an MLG ''A'' frame assembly if it does not incorporate this improved design configuration.

(c) Installing both P/N 105–810023–75 (left) and P/N 105–810023–76 (right) MLG ''A'' frame assemblies eliminates the repetitive inspection requirement of this AD.

(d) Special flight permits may be issued in accordance with sections 21.197 and 21.199 of the Federal Aviation Regulations (14 CFR 21.197 and 21.199) to operate the airplane to a location where the requirements of this AD can be accomplished.

(e) An alternative method of compliance or adjustment of the compliance time that provides an equivalent level of safety may be approved by the Manager, Wichita Aircraft Certification Office (ACO), 1801 Airport Road, Room 100, Mid-Continent Airport, Wichita, Kansas 67209. The request shall be forwarded through an appropriate FAA Maintenance Inspector, who may add comments and then send it to the Manager, Wichita ACO.

Note 2: Information concerning the existence of approved alternative methods of compliance with this AD, if any, may be obtained from the Wichita ACO.

(f) The inspection required by this AD shall be done in accordance with Raytheon Mandatory Service Bulletin No. 2361, Revision III, dated June 1996. This incorporation by reference was approved by the Director of the Federal Register in accordance with 5 U.S.C. 552(a) and 1 CFR part 51. Copies may be obtained from the Raytheon Aircraft Company, P.O. Box 85, Wichita, Kansas 67201–0085. Copies may be inspected at the FAA, Central Region, Office of the Assistant Chief Counsel, Room 1558, 601 E. 12th Street, Kansas City, Missouri, or at the Office of the Federal Register, 800 North Capitol Street, NW., suite 700, Washington, DC.

(g) This amendment (39–9967) supersedes AD 91–14–14, Amendment 39–7055.

(h) This amendment (39–9967) becomes effective on May 16, 1997. Issued in Kansas City, Missouri, on March 6, 1997.

Michael Gallagher,

Manager, Small Airplane Directorate, Aircraft Certification Service.

[FR Doc. 97–6539 Filed 3–18–97; 8:45 am]

BILLING CODE 4910–13–U

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 73

[Docket No. 91C–0189]

Listing of Color Additives for Coloring Contact Lenses; 1,4-Bis[(2-hydroxyethyl)amino]-9,10-anthracenedione bis(2-propenoic)ester copolymers; Confirmation of Effective Date

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule; confirmation of effective date.

SUMMARY: The Food and Drug Administration (FDA) is confirming the effective date of November 5, 1996, for the final rule that amended the color additive regulations to provide for the safe use of the colored reaction products formed by copolymerizing 1,4-bis[(2-hydroxyethyl)amino]-9,10-anthracenedione bis(2-propenoic)ester either with glyceryl methacrylate/methyl methacrylate/ethylene glycol dimethacrylate monomers or with *N*,*N*-dimethyl acrylamide/methyl methacrylate/ethylene glycol dimethacrylate monomers to form contact lenses.

DATES: Effective date confirmed: November 5, 1996.

FOR FURTHER INFORMATION CONTACT: Helen R. Thorsheim, Center for Food Safety and Applied Nutrition (HFS–216), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–418–3092.

SUPPLEMENTARY INFORMATION: In the Federal Register of October 3, 1996 (61 FR 51584), FDA amended 21 CFR part 73 to provide for the safe use of the colored reaction products formed by copolymerizing 1,4-bis[(2-hydroxyethyl)amino]-9,10-anthracenedione bis(2-propenoic)ester either with glyceryl methacrylate/methyl methacrylate/ethylene glycol dimethacrylate monomers or with *N*,*N*-dimethyl acrylamide/methyl methacrylate/ethylene glycol dimethacrylate monomers to form contact lenses.

FDA gave interested persons until November 4, 1996, to file objections or requests for a hearing. The agency received no objections or requests for a hearing on the final rule. Therefore, FDA finds that the final rule published in the Federal Register of October 3, 1996, should be confirmed.

List of Subjects in 21 CFR Part 73

Color additives, Cosmetics, Drugs, Medical devices.

Therefore, under the Federal Food, Drug, and Cosmetic Act (secs. 201, 401, 402, 403, 409, 501, 502, 505, 601, 602, 701, 721 (21 U.S.C. 321, 341, 342, 343, 348, 351, 352, 355, 361, 362, 371, 379e)) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10), notice is given that no objections or requests for a hearing were filed in response to the October 3, 1996, final rule. Accordingly, the amendments promulgated thereby became effective November 5, 1996.

Dated: March 5, 1997.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 97–6849 Filed 3–18–97; 8:45 am]

BILLING CODE 4160–01–F

21 CFR Part 558

New Animal Drugs for Use in Animal Feeds; Bacitracin Methylene Disalicylate and Chlortetracycline

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a new animal drug application (NADA) filed by Alpharma Inc. The NADA provides for using currently approved, single ingredient, Type A medicated articles in making combination drug, Types B and C medicated, swine feeds containing bacitracin methylene disalicylate and chlortetracycline. The Type C medicated feed is used for increased rate of weight gain and improved feed efficiency due to the activity of bacitracin, and treatment of enteritis and pneumonia caused by certain bacteria susceptible to chlortetracycline.

EFFECTIVE DATE: March 19, 1997.

FOR FURTHER INFORMATION CONTACT: George K. Haibel, Center for Veterinary Medicine (HFV–133), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–1644.

SUPPLEMENTARY INFORMATION: Alpharma Inc., One Executive Dr., Fort Lee, NJ 07024, filed NADA 141–059, which provides for combining separately approved, Type A medicated articles containing BMD® (bacitracin methylene disalicylate (bacitracin MD)) and CTC (chlortetracycline) in making combination drug, Type C medicated swine feed. The Type C medicated feed

contains 10 to 30 grams (g) of bacitracin MD and approximately 400 g of CTC per ton varying with body weight and food consumption to provide 10 milligrams of CTC per pound of body weight per day. The feed is indicated for increased rate of weight gain and improved feed efficiency due to the activity of bacitracin, and treatment of bacterial enteritis caused by *Escherichia coli* and *Salmonella choleraesuis* and bacterial pneumonia caused by *Pasteurella multocida* susceptible to CTC. The NADA is approved as of September 18, 1996, and the regulations are amended by revising 21 CFR 558.76(d)(1) and by adding 21 CFR 558.128(c)(3)(xiv) to reflect the approval. The basis for approval is discussed in the freedom of information summary.

In accordance with the freedom of information provisions of part 20 (21 CFR part 20) and § 514.11(e)(2)(ii) (21 CFR 514.11(e)(2)(ii)), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857, between 9 a.m. and 4 p.m., Monday through Friday.

Under section 512(c)(2)(ii) of the Federal Food, Drug, and Cosmetic Act, this approval does not qualify for marketing exclusivity because the application contains no new clinical or field investigations (other than bioequivalence or residue studies) essential to the approval of the application and conducted or sponsored by the applicant.

The agency has determined under 21 CFR 25.24(d)(1)(ii) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

List of Subjects in 21 CFR Part 558

Animal drugs, Animal feeds.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 558 is amended as follows:

PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

1. The authority citation for 21 CFR part 558 continues to read as follows:

Authority: Secs. 512, 701 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b, 371).

2. Section 558.76 is amended in the table in paragraph (d)(1) under entry (iv) by adding a new item for Chlortetracycline approximately 400 to read as follows:

§ 558.76 Bacitracin methylene disalicylate.

* * * * *

(d) * * *

(1) * * *

Bacitracin methylene disalicylate in grams per ton	Combination in grams per ton	Indications for use	Limitations	Sponsor
* *	*	*	* *	*
(iv) 10 to 30	* * *	* * *	* * *	* * *
	Chlortetracycline approximately 400, varying with body weight and food consumption to provide 10 milligrams per pound of body weight per day.	Swine; for increased rate of weight gain and improved feed efficiency; for treatment of bacterial enteritis caused by *Escherichia coli* and *Salmonella choleraesuis* and bacterial pneumonia caused by *Pasteurella multocida* susceptible to chlortetracycline.	Feed for not more than 14 days to provide 10 milligrams of chlortetracycline per pound of body weight per day; as chlortetracycline provided by No. 046573 in § 510.600(c) of this chapter.	046573
* *	*	*	* *	*

* * * * *

3. Section 558.128 is amended by adding new paragraph (c)(3)(xiv) to read as follows:

§ 558.128 Chlortetracycline.

* * * * *

(c) * * *

(3) * * *

(xiv) Bacitracin methylene disalicylate in accordance with § 558.76.

Dated: February 6, 1997.

Stephen F. Sundlof,

Director, Center for Veterinary Medicine.

[FR Doc. 97–6876 Filed 3–18–97; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

24 CFR Part 206

[Docket No. FR–2958–F–07]

RIN 2502–AF32

Home Equity Conversion Mortgage Insurance Demonstration: Additional Streamlining; Correction

AGENCY: Office of the Assistant Secretary for Housing-Federal Housing Commissioner, HUD.

ACTION: Final rule; Correction.

SUMMARY: On September 17, 1996 (61 FR 49030), the Department issued a final rule to the changes proposed on May 10, 1996, to the Home Equity Conversion Mortgage (HECM) Insurance Demonstration. The final rule had an effective date of October 17, 1996, except that the amendment to the definition of ''principal limit'' in § 206.3, had a delayed effective date of January 5, 1997. On December 26, 1996 (61 FR 67930), the Department further delayed the effective date of the definition of ''principal limit'' in § 206.3 until May 1, 1997, but inadvertently did not change the date as it was set forth within the definition in two places. Today's notice corrects the references to the date contained in the definition of ''principal limit,'' as it was set forth in the December 26, 1996 publication to conform to the intent of the December